Health InsuranceCovidien Announces Health Canada Approval For Its Generic Myocardial Perfusion Imaging Kit
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Health Canada has approved the Company"s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien"s generic product is fully substitutable for Cardiolite®, a myocardial perfusion imaging agent used for detecting coronary artery disease.
With Health Canada approval of the ANDS, which was filed by the Company"s Canadian subsidiary, Covidien"s generic product is expected to be available for customers in Canada this summer. The Company"s generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.
"We are pleased to receive approval in Canada and to introduce this generic diagnostic option to meet patients" needs," said Timothy R. Wright, President, Pharmaceutical Products and Imaging Solutions, Covidien.
Covidien"s Imaging Solutions business is a leading provider of radiopharmaceuticals used in nuclear medicine imaging procedures. It also supplies contrast media delivery systems, which combine contrast media and power injectors, for Computed Tomography (CT), X-ray and Magnetic Resonance Imaging (MRI) procedures.
Covidien